186 related articles for article (PubMed ID: 38342136)
1. Fertility Potential and Gonadal Function in Survivors of Reduced-Intensity Hematopoietic Stem Cell Transplantation.
Rotz SJ; Hamilton BK; Wei W; Ahmed I; Winston SA; Ballard S; Bernard RJ; Carpenter P; Farhadfar N; Ferraro C; Friend BD; Gloude NJ; Hayashi RJ; Hoyle K; Jenssen K; Koo J; Lee CJ; Mariano L; Nawabit R; Ngwube A; Lalefar N; Phelan R; Perkins L; Rao A; Rayes A; Sandheinrich T; Stafford L; Tomlinson K; Whiteside S; Wiedl C; Myers K
Transplant Cell Ther; 2024 May; 30(5):534.e1-534.e13. PubMed ID: 38342136
[TBL] [Abstract][Full Text] [Related]
2. Reduced-Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplantation.
Bender JD; Oquendo-Del Toro H; Benoit J; Howell JC; Badia P; Davies SM; Grimley MS; Jodele S; Phillips C; Burns K; Marsh R; Nelson A; Wallace G; Dandoy CE; Pate A; Strine AC; Frias O; Breech L; Rose SR; Hoefgen H; Khandelwal P; Myers KC
Transplant Cell Ther; 2023 Feb; 29(2):130.e1-130.e8. PubMed ID: 36323400
[TBL] [Abstract][Full Text] [Related]
3. Female Reproductive Health Outcomes after Hematopoietic Cell Transplantation for Sickle Cell Disease: Is Reduced Intensity Better Than Myeloablative Conditioning?
Meacham LR; George S; Veludhandi A; Pruett MC; Haight AE; Arnold SD; Elchuri S; Stenger E; Krishnamurti L
Transplant Cell Ther; 2023 Aug; 29(8):531.e1-531.e4. PubMed ID: 37169288
[TBL] [Abstract][Full Text] [Related]
4. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Nath K; Peterson K; Brown S; Devlin S; Rodriguez N; Barker J; Giralt S; Gyurkocza B; Jakubowski A; Papadopoulos E; Ponce D; Scordo M; Shah G; Perales MA; Sauter C; Lin A; Dahi PB
Transplant Cell Ther; 2024 Jan; 30(1):81-92. PubMed ID: 37788792
[TBL] [Abstract][Full Text] [Related]
5. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.
Oran B; Wagner JE; DeFor TE; Weisdorf DJ; Brunstein CG
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1327-34. PubMed ID: 21232621
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Anti-Mullerian Hormone Levels Pre- and Post-Hematopoietic Cell Transplantation in Pediatric and Adolescent Females with Sickle Cell Disease.
George SA; Lai KW; Lewis RW; Bryson EW; Haight AE; Meacham LR
Transplant Cell Ther; 2022 Nov; 28(11):770.e1-770.e6. PubMed ID: 35995392
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the ovarian reserve with anti-Müllerian hormone in women who underwent allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning regimens or myeloablative regimens with ovarian shielding.
Nakano H; Ashizawa M; Akahoshi Y; Ugai T; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Kako S; Kanda J; Yamazaki R; Tanihara A; Nishida J; Kanda Y
Int J Hematol; 2016 Jul; 104(1):110-6. PubMed ID: 27084256
[TBL] [Abstract][Full Text] [Related]
8. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
[TBL] [Abstract][Full Text] [Related]
9. Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning.
Phelan R; Mann E; Napurski C; DeFor TE; Petryk A; Miller WP; Wagner JE; Verneris MR; Smith AR
Bone Marrow Transplant; 2016 Oct; 51(10):1369-1375. PubMed ID: 27272448
[TBL] [Abstract][Full Text] [Related]
10. Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant.
Higgins A; Khan Z; Coddington CC; Hashmi SK; Hefazi M; Alkhateeb H; Litzow MR; Hogan WJ; Cathcart-Rake E; Thompson CA; Patnaik MM
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1232-1239. PubMed ID: 30772513
[TBL] [Abstract][Full Text] [Related]
11. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.
Abdul Wahid SF; Ismail NA; Mohd-Idris MR; Jamaluddin FW; Tumian N; Sze-Wei EY; Muhammad N; Nai ML
Stem Cells Dev; 2014 Nov; 23(21):2535-52. PubMed ID: 25072307
[TBL] [Abstract][Full Text] [Related]
12. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
13. Gonadal function and fertility after stem cell transplantation in childhood: comparison of a reduced intensity conditioning regimen containing melphalan with a myeloablative regimen containing busulfan.
Panasiuk A; Nussey S; Veys P; Amrolia P; Rao K; Krawczuk-Rybak M; Leiper A
Br J Haematol; 2015 Sep; 170(5):719-26. PubMed ID: 25974284
[TBL] [Abstract][Full Text] [Related]
14. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
15. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Scott BL; Pasquini MC; Logan BR; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick ED; Fernandez HF; Alyea EP; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Le-Rademacher J; Mendizabal AM; Horowitz MM; Deeg HJ; Horwitz ME
J Clin Oncol; 2017 Apr; 35(11):1154-1161. PubMed ID: 28380315
[TBL] [Abstract][Full Text] [Related]
16. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
17. Inhibin B and anti-Müllerian hormone as markers of gonadal function after hematopoietic cell transplantation during childhood.
Laporte S; Couto-Silva AC; Trabado S; Lemaire P; Brailly-Tabard S; Espérou H; Michon J; Baruchel A; Fischer A; Trivin C; Brauner R
BMC Pediatr; 2011 Feb; 11():20. PubMed ID: 21352536
[TBL] [Abstract][Full Text] [Related]
18. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
19. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison.
Sharma P; Pollyea DA; Smith CA; Purev E; Kamdar M; Haverkos B; Sherbenou D; Rabinovitch R; Hammes A; Gutman JA
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1671-1677. PubMed ID: 29684565
[TBL] [Abstract][Full Text] [Related]
20. Updated Clinical Outcomes of Hematopoietic Stem Cell Transplantation Using Myeloablative Total Body Irradiation with Ovarian Shielding to Preserve Fertility.
Ashizawa M; Akahoshi Y; Nakano H; Kawamura S; Takeshita J; Yoshino N; Misaki Y; Yoshimura K; Gomyo A; Tamaki M; Kusuda M; Kameda K; Wada H; Kawamura K; Sato M; Terasako-Saito K; Tanihara A; Kimura SI; Nakasone H; Kako S; Akahane K; Wakatsuki M; Shirai K; Kanda Y
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2461-2467. PubMed ID: 31394267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
